We have located links that may give you full text access.
Phase and morphological control of MoO 3-x nanostructures for efficient cancer theragnosis therapy.
Nanoscale 2017 August 11
Nanostructures of metal oxide semiconductors play significant roles in a variety of areas, such as biotherapy, pollutant treatment and energy storage and conversion. The molybdenum oxide (MoO3-x ) nanostructures have shown promising applications especially when used as photothermal treatment agents due to their relatively low cost, facile synthesis and low toxicity. However, the design and synthesis of efficient MoO3-x nanomaterials with tunable phases and morphologies for theragnosis of tumors remains a challenge. In this work, hydrophilic MoO3-x with controlled structures and phases was synthesized by a simple one-step hydrothermal process. The as-obtained MoO2 nanoclusters showed a desirable size of ∼40 nm in diameter exhibiting unique properties as a theragnosis nanoplatform: (1) strong near-infrared absorption, which is due to oxygen vacancies of the nanoclusters, as proved by photoluminescence spectroscopy and X-ray photoelectron spectroscopy; (2) excellent photothermal performance with a photothermal conversion efficiency of up to 62.1%; and (3) the image response of X-ray computed tomography (CT) and infrared thermal imaging for simultaneous diagnosis of tumors. This study provided the facile synthetic strategy for controllable metal oxide semiconductors and promoted the development of metal oxides for theragnosis therapy of cancers.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app